RIGL — Rigel Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $761.27m
- $683.85m
- $179.28m
- 76
- 77
- 99
- 97
Annual income statement for Rigel Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 109 | 149 | 120 | 117 | 179 |
| Cost of Revenue | |||||
| Gross Profit | 108 | 148 | 118 | 110 | 161 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 138 | 162 | 176 | 137 | 155 |
| Operating Profit | -29 | -12.5 | -55.5 | -20.5 | 24.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -29.7 | -17.3 | -58.6 | -25.1 | 18.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -29.7 | -17.9 | -58.6 | -25.1 | 17.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -29.7 | -17.9 | -58.6 | -25.1 | 17.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -29.7 | -17.9 | -58.6 | -25.1 | 17.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.76 | -0.916 | -3.32 | -1.44 | 0.989 |